Zevra Therapeutics, Inc.
ZVRA
$8.31
$0.374.66%
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Net Income | -7.57% | -66.75% | -19.87% | 16.44% | -91.88% |
| Total Depreciation and Amortization | 1.92% | 3.52% | 0.00% | 98.48% | 1,169.35% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 65.29% | 1,874.93% | 172.52% | -117.44% | 363.85% |
| Change in Net Operating Assets | -1,913.81% | 83.40% | -872.97% | 94.18% | -132.76% |
| Cash from Operations | 10.42% | 5.07% | -18.21% | -0.04% | -249.14% |
| Capital Expenditure | -- | -- | -- | -- | 58.14% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 82.55% | -24,205.43% | -100.87% | -63.97% | 192.72% |
| Cash from Investing | 82.55% | -24,205.43% | -100.87% | 39.75% | 123.81% |
| Total Debt Issued | -- | -100.00% | -- | -- | -86.04% |
| Total Debt Repaid | -- | 100.00% | -- | -- | -2,407.80% |
| Issuance of Common Stock | -98.77% | 13,392.71% | -60.56% | -80.07% | 11,418.87% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | 100.00% | -- | -- | -- |
| Cash from Financing | -98.77% | 322.47% | 1,159.65% | -75.68% | -80.94% |
| Foreign Exchange rate Adjustments | 236.66% | -253.92% | 808.89% | -112.89% | 442.16% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -237.05% | 511.79% | -1,694.50% | 9.09% | 99.04% |
